Kornimate/medical-research-clean huggingface dataset:
releasing of inflammatory mediators during retreatment of root canals

Conditions: Inflammatory Response; Root Canal Infection

Summary: nonsurgical root canal retreatment may become essential when the initial endodontic treatment fails because of the persistent intracanal or extracanal infections.the aim of this thesis study is to evaluate the effect of protaper universal retreatment (ptur), reciproc blue and xp-endo finisher r file systems, which are used in the removal of root canal filling materials during retreatment with different motion kinetics on the release of substance p, calcitonin gene-related peptide (cgrp), il-6 and il-10 inflammatory mediators in the periapical region

seventy-five individuals with asymptomatic and chronic apical periodontitis teeth with retreatment indication were included in the study. individuals were randomly divided into three groups according to the file system used to remove root canal filling materials (n = 25): protaper universal retreatment, reciproc blue and xp-endo finisher r.after the removal of the previous root canal filling materials, reshaping and disinfection of the root canals, periapical fluid samples were taken from the root tip of the teeth in all three groups. the amount of substance p, cgrp, il-6 and il-10 mediators that cause pain, swelling and flare-up in periapical fluid samples were measured by elisa test.

Eligibility criteria:
inclusion criteria: * patients who had single root canal treated teeth with chronic periapical lesion exclusion criteria: * patients who are immunocompromised * patients under antibiotic or analgesic medication
combination chemotherapy in treating patients with advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. leucovorin may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the drug. purpose: phase ii trial to study the effectiveness of combination chemotherapy consisting of oxaliplatin, fluorouracil, and leucovorin in treating patients who have colorectal cancer.

objectives: i. evaluate the quantitative and qualitative toxicities of oxaliplatin combined with fluorouracil and leucovorin calcium in patients with advanced adenocarcinoma of the colon or rectum. outline: patients receive leucovorin calcium iv over 10-20 minutes followed within 10 minutes by fluorouracil iv bolus on days 1, 8, 15, 29, 36, and 43. patients receive oxaliplatin iv over 2 hours prior to leucovorin calcium and fluorouracil on days 1, 15, 29, and 43. treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. patients with stable or responding disease may receive additional courses upon approval by the sponsor. patients are followed at 30 days. projected accrual: a total of 18-35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven advanced adenocarcinoma of the colon or rectum no prior systemic chemotherapy or adjuvant chemotherapy only, completed 6 months prior to study and with subsequent development of recurrent disease at least 1 bidimensionally measurable lesion no cns metastases patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: greater than 12 weeks hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 2.0 mg/dl (no greater than 5.0 mg/dl if due to intrahepatic biliary obstruction not amenable to biliary decompression, if approved by the protocol investigator) sgot no greater than 4 times upper limit of normal renal: creatinine no greater than 1.5 mg/dl cardiovascular: no myocardial infarction within the past 6 months no congestive heart failure other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no neurologic disease no active or uncontrolled infection no other malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix no medical or psychiatric disorders that would prevent compliance prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: no prior radiotherapy for malignant disease surgery: recovered from any prior surgery other: at least 30 days since other prior investigational agent no other concurrent investigational agents no concurrent anticancer agents

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
impact of dedicated hygienist staff on the occurrence of intensive care unit -aquired bloodstream infections

Conditions: Intensive Care Unit -Aquired Bloodstream Infections.

Summary: the purpose of this study is to evaluate in a multicentric cluster randomized study the effect of the presence of dedicated nurses for training of icu staff in preventing nosocomial infections. the rate of bloodstream infections per 100 admitted patients is used as the main endpoint. a sample of 4000 included patients in the 6 participating icu is included with the objective to show a reduction of one third of the rate of icu-acquired bloodstream infections. the study is currently at the end of the recrutimeent phase.

15% of patients admitted to intensive care have an infection acquired in the service, including bacteremia is a serious form. compliance with hygiene measures and recommendations in the use of invasive devices can reduce the incidence. the advantage of simple recommendations type "bundle" could, however, be insufficient because not associated with training and monitoring compliance with the recommendations. the aim of this study is to show that the daily intervention of a public health nurse on the basis of a half full-time equivalent, allows these actions and therefore a reduction in the bloodstream of the attack rate acquired in the icu compared dissemination of simple recommendations.

Eligibility criteria:
inclusion criteria: * patients admitted to reanimation department exclusion criteria: * no exclusion criteria
minoxidil response testing in females with female pattern hair loss

Conditions: Alopecia; Female Pattern Hair Loss

Summary: the primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.

topical minoxidil is the only us fda approved drug used for the treatment of aga in females. while topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. to observe significant improvement in hair growth, minoxidil is typically used once daily for a period of at least 24 weeks. due to the significant time commitment and low response rate, a diagnostic test to identify non-responders prior to initiating therapy would be advantageous. minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme sult1a1. the enzyme expression is variable among individuals. we have demonstrated in two prior feasibility studies that the sult1a1 enzyme activity in plucked hair follicles correlates with minoxidil response in the treatment of aga and thus can server as a predictive biomarker. consequently, we developed a minoxidil response in-vitro diagnostic kit intended to identify non-responders prior to initiating therapy with 5% topical minoxidil foam.

Eligibility criteria:
inclusion criteria: * females in overall good health * age: 18 or older * female pattern hair loss * willing to have a mini dot tattoo placed in the target area of the scalp * willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study * able to give informed consent * able to comply with the study requirements for 24 consecutive weeks * willing to use an adequate method of birth control (if applicable) * negative urine pregnancy test exclusion criteria: * previous adverse event from topical minoxidil treatment * history of hypotension * uncontrolled hypertension * pregnant, nursing, or planning a pregnancy during the study * prior hair transplant * uses wigs or hair weaves * have used minoxidil (topical or oral) anytime during the past 6 months * chronic scalp disorders that require medications * uses medication known to cause hair thinning such as coumadin and anti-depressants/anti-psychotics * folliculitis * scalp psoriasis * seborrheic dermatitis * inflammatory scalp conditions such as lichen planopilaris * enrolled in any other medical study or has been enrolled in any medical study in the past 6 months

Keywords: alopecia androgenetic alopecia female pattern hair loss hair loss minoxidil hair thinning
noninvasive methods to monitor graft survival in kidney transplant patients

Conditions: Kidney Transplantation

Summary: the purpose of this study is to test noninvasive methods to monitor the health and condition of new kidneys in people who have received kidney transplants.

innovations in kidney transplantation have improved short-term outcomes for transplant patients. however, organ rejection remains as an important threat to the long-term survival of the transplanted organ. if clinicians could better monitor the condition of the organ after transplantation, they may be able to improve the chance of graft survival. noninvasive ways to monitor the condition of the transplanted organ need to be developed and tested. this observational study will investigate whether certain blood and urine tests are useful in monitoring the health of transplanted kidneys. this trial will involve 14 post-transplant study visits over the course of 2 years. a physical exam, medication history, adverse events assessment, and blood and urine collection will occur at all visits. kidney biopsies will occur at study entry prior to transplantation and at month 6, in adult participants only. protocol biopsies are optional in the pediatric substudy group. additional visits may be required if organ rejection is suspected.

Eligibility criteria:
inclusion criteria: * candidate for deceased donor or living donor kidney transplant * negative crossmatch * parent or guardian willing to provide informed consent, if applicable exclusion criteria: * clinically significant liver disease * other illnesses that, in the opinion of the investigator, may interfere with the study * recipient of multiple organ transplants * inability or unwillingness to comply with the study protocol

Keywords: kidney transplant rejection kidney disease kidney failure end stage renal disease
prediabetes and newly diagnosed diabetes in chronic heart failure

Conditions: Chronic Heart Failure

Summary: the aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with chf(chronic heart failure) in sohag university hospital patients .

- prospective study to: 1. study the differences in the prevalence of prediabetes and newly diagnosed diabetes among the patients with hfref and hfpef 2. the effect of dysglycemia on prognosis of patients with chronic heart failure. 3. the effect of early discover of diabetes mellitus on prognosis of patients with chronic heart failure

Eligibility criteria:
inclusion criteria: * all patients presented by heart failure * 18 years or older * classified according to nyha " new york heart association" classification from nyha class 2 and more exclusion criteria: * overt diabetes * rheumatic heart disease * congenital heart disease
the effect of acupressure, laughter yoga and mindfulness on menopausal symptoms and quality of life

Conditions: Menopausal Symptoms; Quality of Life

Summary: the aim of the study is to determine the effect of acupressure, laughter yoga and mindfulness stress reduction program on menopausal symptoms and quality of life.menopausal period, which is one of the life stages, causes physiological changes and can decrease the quality of life. the research is a randomized controlled trial. 180 women who meet the conditions for research will be included in the study. three instruments were used to obtain the research data: personal information form,menopausal symptoms rating scale and menopause-specific quality of life scale.

on average, one third of a woman's life passes during menopause. the menopausal period is an important period that brings many physical and psychological changes with it and significantly affects the disease process and the family and society. cultural and ethnic characteristics of the society are among the important factors that affect women's attitudes towards menopause and the meaning of middle age for women.women seek ways to deal with menopausal symptoms. women prefer drug-free coping methods. mindfulness stress reduction program, yoga and laughter yoga are an alternative way to reduce menopausal symptoms.. these methods can reduce the complaints and increase the quality of life. for this reason, the effect should be determined in the menopausal period.

Eligibility criteria:
inclusion criteria: * in the menopausal period exclusion criteria: * presence of psychiatric illness using psychiatric medication
assessment of the interest of ani in the non-communicating patient in palliative care

Conditions: End of Life; Pain; Analgesia

Summary: comfort evaluation is one of the major challenges in the palliative care setting, particularly when it comes to non-communicative patients. ani monitoring is a non-invasive and painless technique which evaluates the parasympathetic tone activity through heart rate variability. it has proven reliable for pain assessment during general anesthesia (ga) or for sedated critically ill patients. the parasympathetic activity seems to be a good reflect of the patient's comfort, implicating stress and anxiety. so, the ani could be an interesting tool to assess the comfort of non-communicating end-of-life patients. that is why the goal of our study is to assess the interest of ani to assess the comfort of non-communicating patients hospitalized in palliative care during a painful care by comparing the ani measure to the cpot scale realised by the nurses in a blind manner.


Eligibility criteria:
inclusion criteria: * hospitalized in palliative care non-communicating patients (glasgow ≤ 10) exclusion criteria: * non sinusal heart rate * respiratory rate \< 9/min * treated by inotropes * pace-maker * patient in agonal phase * opposition from the guardian

Keywords: analgesia/nociception index end-of-life, comfort evaluation, comfort monitoring, palliative care, non-communicating comfort evaluation comfort monitoring palliative care non-communicating
a randomized, comparative, double-blind trial of pentaisomaltose and dimethyl sulphoxide for cryoprotection of hematopoietic stem cells in subjects with multiple myeloma or malignant lymphoma with a need for autologous transplantation

Conditions: Malignant Lymphoma; Multiple Myeloma

Summary: a randomized, comparative, double-blind trial of pentaisomaltose and dimethyl sulphoxide for cryoprotection of hematopoietic stem cells in subjects with multiple myeloma or malignant lymphoma with a need for autologous transplantation

the trial is a randomized, comparative, double-blind trial comparing the efficacy and safety of pentaisomaltose (pentahibe®, pharmacosmos a/s, holbæk; termed pim in the following) and dimethyl sulphoxide (dmso), when used for preservation of harvested hematopoietic stem cells. approximately 150 subjects with a diagnosis of multiple myeloma or malignant lymphoma (a minimum of 30 % of each diagnosis and an equal distribution in each preservation group) and undergoing autologous stem cell transplantation (asct) will be included. the subjects will be randomized 1:1 to receive asct preserved in the following cryo-protective agent (cpa): * a: pim 16 % * b: dmso 10 %

Eligibility criteria:
inclusion criteria: * men or women ≥ 18 years * multiple myeloma or malignant lymphoma diagnosis in which asct is indicated according to the standard procedures at the hospital * willing to be hospitalized for minimum 24 hours after the asct * willingness to participate and signing the icf exclusion criteria: * multiple myeloma or lymphoma invasion of the central nervous system * previous treatment with asct * severe infection * unsuitable for apheresis * unable to provide ≥3 bags with a cell concentration ≥2.0×106 cd34+ cells/kg bodyweight per bag during apheresis * pregnant or nursing women. to avoid pregnancy, women of childbearing potential have to use adequate contraception (e.g., intrauterine devices, hormonal contraceptives, or double barrier method) during the whole trial period and up to 1 year after the last asct * men, even if surgically sterilized, (i.e., status post vasectomy), who do not agree to practice effective barrier contraception during the entire trial period and through 6 months after the last asct, or agrees to completely abstain from heterosexual intercourse * any other medical condition which, in the opinion of the investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements
procalcitonin test for differentiation of the cause of pneumonia

Conditions: Procalcitonin; Pneumonia; Cancer

Summary: the purpose of this study is to evaluate the usefulness of procalcitonin test for differentiation of the cause of pneumonia in patients with cancer.

serum procalcitonin test is currently used as the biomarker for bacterial infection. especially, procalcitonin test has been reported to be helpful in differentiating bacterial pneumonia from viral pneumonia, acute exacerbations of interstitial pneumonitis or chronic obstructive lung disease. however, it is not known whether procalcitonin test can help distinguish bacterial pneumonia from non-bacterial pneumonia such as radiation pneumonitis or chemotherapy-induced pneumonitis in patients with cancer. the aim of this prospective cohort study is to observe the clinical benefits of procalcitonin test for differentiation of the cause of pneumonia in patients with cancer.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * patients who have symptoms and suspected imaging findings compatible with pneumonia exclusion criteria: * patients who have been treated with antibiotics or steroid therapy.
a validation study of a new system for measuring the end expiratory lung volume during mechanical ventilation

Conditions: Respiratory Failure

Summary: in this study the investigators aim to evaluate a new system dedicated to estimate the end expiratory lung volume, by measuring the vo2-vco2, during mechanical ventilation compared to the helium dilution technique and the computed tomography (ct) scan.

in this study we aimed to evaluate a new system dedicated to estimate the end expiratory lung volume, by measuring the vo2-vco2, during mechanical ventilation compared to the helium dilution technique and the ct scan. we will compare the data considering the ct scan data as the gold standard.

Eligibility criteria:
inclusion criteria: * adult intubated subjects exclusion criteria: * barotrauma

Keywords: acute respiratory failure
effect of hyperbaric oxygen therapy(hbot) on patients with sudden sensorineural hearing loss(ssnhl) and coagulation function

Conditions: Sudden Sensorineural Hearing Loss (SSNHL); Hyperbaric Oxygen Therapy

Summary: the objective of this observational study was to understand the effect of hbo on patients with ssnhl and its association with coagulation function and prognosis. the main question it aims to answer is whether hbo therapy can improve outcomes and coagulation function in patients with ssnhl. the prognosis of ssnhl patients receiving hbo and ssnhl patients not receiving hbo were compared


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for sudden deafness in the american academy of otolaryngology head and neck surgery 2019 clinical practice guidelines for sudden deafness; * aged 18-75 years old; * patients with unilateral sudden deafness for the first time, and the onset time is less than 2 weeks. exclusion criteria: * patients with other ear diseases, such as auditory trauma, barotrauma, retrocochlear disease, bilateral hearing loss, history of chronic otitis media in the same ear, and history of surgery in the same ear; * patients with serious primary diseases such as heart, liver, kidney dysfunction and hematopoietic system diseases; * pregnant and nursing patients; * accompanied by serious mental illness; * patients with incomplete clinical data.
comparing uretersocopy with versus without use of guide-wire in treatment of ureteral stone

Conditions: Ureteral Calculi

Summary: the purpose of this study is to compare ureteroscopy with and without use of safety guide-wire in treatment of ureteral stone

while there are some retrospective studies compared ureteroscopy with and without use of safety guide-wire in treatment of ureteral stone, there is not randomized clinical trial in this regard. this study was designed to compare the efficacy and safety of ureteroscopy with and without use of safety guide-wire in treatment of ureteral stone

Eligibility criteria:
inclusion criteria: * ureteral stone who underwent ureteroscopy exclusion criteria: * transplant kidney * coagulopathy disorders * history of ureteral stenosis * skeletal disorders

Keywords: ureteral calculi safety guide-wire ureteroscopy
observational study evaluating the efficacy and safety of zanubrutinib in participants with waldenström macroglobulinemia

Conditions: Waldenstrom Macroglobulinemia

Summary: this is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in waldenström macroglobulinemia (wm) participants with and without specific mutations and from racial and ethnic minority groups. data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.


Eligibility criteria:
inclusion criteria: * clinical and definitive histologic diagnosis of wm * measurable disease, as defined by a serum immunoglobulin m (igm) level \> 0.5 g/dl at the time of zanubrutinib initiation * started treatment with zanubrutinib, has been treated with zanubrutinib, or is planned to be prescribed zanubrutinib for the treatment of wm * bone marrow specimens with central myd88 test results of: 1. cohort 1: myd88 l265p mutation; enrollment of tn participants will be stopped in each racial and ethnic participant group when the required numbers of participants in the group are met 2. cohort 2: non-l265p myd88 mutation(s) and myd88wt exclusion criteria: * evidence of disease transformation before the first dose of zanubrutinib * evidence of other non-hodgkin lymphoma (nhl) subtypes * prior or concurrent active malignancy ≤ 2 years before the first dose of zanubrutinib, except for malignancies that, in the investigator's opinion, will not obscure the interpretation of safety or efficacy results * concurrent participation in another therapeutic clinical study while receiving zanubrutinib, although the participant may be eligible depending on the status of the interventional study after discussion with the medical monitor or designee on an individual basis